Overview

Variant Type
Fusion
Genes
ABL1 and BCR

BCR-ABL1 Fusion is present in 0.21% of AACR GENIE cases, with chronic myeloid leukemia, breast invasive ductal carcinoma, unknown, B-cell lymphoblastic leukemia/lymphoma, and acute myeloid leukemia having the greatest prevalence [4].

Top Disease Cases with BCR-ABL1 Fusion

Biomarker-Directed Therapies

Significance of BCR-ABL1 Fusion in Diseases

Chronic Myeloid Leukemia +

Acute Lymphoblastic Leukemia +

Acute Myeloid Leukemia +

Myelodysplastic Syndromes +

Hodgkin Lymphoma +

Multiple Myeloma +

Non-Hodgkin Lymphoma +

Acute Biphenotypic Leukemia +

B-Cell Acute Lymphoblastic Leukemia +

Chronic Lymphocytic Leukemia +

Chronic Myelomonocytic Leukemia +

Acute Leukemia +

Mantle Cell Lymphoma +

Burkitt Lymphoma +

Myeloproliferative Neoplasm +

Anaplastic Large Cell Lymphoma +

Follicular Lymphoma +

Juvenile Myelomonocytic Leukemia +

Marginal Zone Lymphoma +

Secondary Acute Myeloid Leukemia +

Lymphoma +

Lymphoblastic Lymphoma +

Myelofibrosis +

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma +

Diffuse Large B-Cell Lymphoma +

Prolymphocytic Leukemia +

Refractory Anemia With Excess Blasts +

T-Cell Acute Lymphoblastic Leukemia +

Mixed Phenotype Acute Leukemia +

Lymphoplasmacytic Lymphoma +

Myelodysplastic/Myeloproliferative Neoplasm +

Small Lymphocytic Lymphoma +

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome +

Acute Undifferentiated Leukemia +

B-Cell Non-Hodgkin Lymphoma +

Double-Hit Lymphoma +

Refractory Anemia +

Therapy-Related Myelodysplastic Syndrome +

Malignant Solid Tumor +

Myelodysplastic Syndrome With Excess Blasts-2 +

Plasma Cell Leukemia +

T-Cell Lymphoblastic Leukemia/Lymphoma +

Therapy-Related Acute Myeloid Leukemia +

Acute Erythroid Leukemia +

Acute Megakaryoblastic Leukemia +

Acute Promyelocytic Leukemia +

Adult T-Cell Leukemia/Lymphoma +

B-Cell Prolymphocytic Leukemia +

Burkitt Leukemia +

Mature T-Cell And NK-Cell Lymphoma/Leukemia +

Mature T-Cell And NK-Cell Neoplasm +

Natural Killer Cell Lymphoblastic Leukemia/Lymphoma +

Peripheral T-Cell Lymphoma +

T-Cell Non-Hodgkin Lymphoma +

T-Cell Prolymphocytic Leukemia +

Acute Leukemia Of Ambiguous Lineage +

Leukemia +

Solid Neoplasm +

Acute Bilineal Leukemia +

Acute Myeloid Leukemia With Myelodysplasia-Related Changes +

Adult Acute Lymphoblastic Leukemia +

Aplastic Anemia +

B-Cell Lymphoblastic Lymphoma +

Desmoplastic Small Round Cell Tumor +

Ewing Sarcoma +

Histiocytic And Dendritic Cell Neoplasm +

Indolent Non-Hodgkin Lymphoma +

Mature B-Cell Lymphoma/Leukemia +

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

Mediastinal Large B-Cell Lymphoma +

Melanoma +

Mixed Phenotype Acute Leukemia, B/Myeloid, NOS +

Mixed Phenotype Acute Leukemia, T/Myeloid, NOS +

Myelodysplastic Syndrome With Excess Blasts-1 +

Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable +

Myeloid Sarcoma +

Neuroblastoma +

Plasma Cell Neoplasm +

Polycythemia Vera +

Primary Myelofibrosis +

Rhabdomyosarcoma +

Secondary Myelodysplastic Syndrome +

Small Lymphocytic Leukemia +

T-Cell Lymphoblastic Lymphoma +

T-Cell And NK-Cell Neoplasm +

Therapy-Related Chronic Myelomonocytic Leukemia +

Therapy-Related Myeloid Neoplasm +

Waldenstrom Macroglobulinemia +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.